Human triple negative breast cancer MDA-MB-231 D3H2LN-Luc derivative cells stably expressing the Tet-On 3G (Tet3G) transactivator and luciferase, enabling the study of cell migration and the development of therapies that inhibit metastasis.
| Inventor | Institute |
|---|---|
| Heather Mckinnon ; Justin Bower ; Daniel Croft | Cancer Research UK, Glasgow: The Beatson Institute |
| SKU: | 154147 |
|---|---|
| Product description: | This cell line stably expresses the Tet-On 3G (Tet3G) transactivator and luciferase and contains a tetracycline inducible promoter construct ready for cloning in a gene of interest. The cell line is a derivative of a human tiple negative breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Unbekandt et al., 2014 introduced their genes of interest, the kinases MRCKβ, ROCK1 and ROCK2 under the tetracycline inducible promoter, to study the impact of their expression and inhibition on migration of the cells. Useful for the study of breast cancer cell cytoskeleton reorganisation, cell migration and the development of therapies that inhibit metastasis. |
| Conditional: | Yes |
| Conditional description: | When a gene of interest is introduced under the control of the tetracycline (Tet)-regulated transactivator Tet-On 3G expression can be induced by administration of doxycycline. Luciferase expression is non-conditional. |
| Production details: | Generated an MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G |
| Additional notes: | Tet-On System owned by TET Systems GmbH & Co. KG. |
| Parental cell line: | MDA-MB-231 D3H2LN-Luc |
| Disease: | Cancer |
| Cat. #: | 154147 |
|---|---|
| Provenance and Ownership: | The MDA-MB-231 D3H2LN-Luc TetOn-3G cell line is owned by Cancer Research UK. CancerTools supplies the MDA-MB-231 D3H2LN-Luc TetOn-3G cell line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing MDA-MB-231 D3H2LN-Luc TetOn-3G cell line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Breast cancer |
| Organism: | Human |
| Tissue: | Breast |
| Model: | Reporter |
| Growth properties: | Adherent cell line |
| Cancer Types In Detail: | Triple negative breast (TNBC) |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | MEM/EBSS (Hyclone) supplemented with 10% Tet system approved fetal bovine serum (FBS) (Clonetech), 1 mM Sodium Pyruvate (Sigma), 2 mM L-glutamine (Gibco), 1× MEM non-essential amino acids (Gibco) plus penicillin-streptomycin (10 Units/ml and 10 μg/ml respectively). |
| Recommended controls: | HeLa TetOn-3G |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Unbekandt et al. 2014. Cell Commun Signal. 12:54. PMID: 25288205. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.